Literature DB >> 17931612

Impact of weight loss on circulating IL-1, IL-6, IL-8, TNF-alpha, VEGF-A, VEGF-C and midkine in gastroesophageal cancer patients.

Malgorzata Krzystek-Korpacka1, Malgorzata Matusiewicz, Dorota Diakowska, Krzysztof Grabowski, Katarzyna Blachut, Irena Kustrzeba-Wojcicka, Teresa Banas.   

Abstract

OBJECTIVE: Proinflammatory cytokines are involved in cancer-related weight loss, but the involvement of VEGF-A, VEGF-C, IL-8 and midkine in gastroesophageal cancer patients remains unknown. DESIGN AND METHODS: Serum IL-1, IL-6, IL-8, TNF-alpha, VEGF-A, VEGF-C, and midkine were evaluated in 96 cancer patients and 42 controls using ELISAs and were related to the occurrence of weight loss, patient's age, gender and BMI, cancer TNM status and blood cell counts.
RESULTS: All cytokines were elevated in cancer patients with further up-regulation of IL-6, IL-8, midkine and VEGF-A in cachexia. Underweight, midkine and VEGF-A were found independent indicators of weight loss. Primary tumor seems to be a major source of pro-cachectic cytokines, yet neutrophils and platelets also contribute to cytokine elevation.
CONCLUSIONS: IL-6 and IL-8, and probably midkine and VEGF-A, appear to participate in the development of cancer-related cachexia in gastroesophageal malignancies, although a detailed mechanism underlying cytokine involvement needs to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17931612     DOI: 10.1016/j.clinbiochem.2007.07.013

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  25 in total

Review 1.  Chemokines, chemokine receptors and the gastrointestinal system.

Authors:  Hiroshi Miyazaki; Kazuaki Takabe; W Andrew Yeudall
Journal:  World J Gastroenterol       Date:  2013-05-21       Impact factor: 5.742

2.  Cachexia - an intrinsic factor in wound healing.

Authors:  Michael F Y Ng
Journal:  Int Wound J       Date:  2010-04       Impact factor: 3.315

3.  Suppression of Ehrlich carcinoma growth by cobra venom factor.

Authors:  T I Terpinskaya; V S Ulashchik; A V Osipov; V I Tsetlin; Yu N Utkin
Journal:  Dokl Biol Sci       Date:  2016-11-08

Review 4.  Off-tumor target--beneficial site for antiangiogenic cancer therapy?

Authors:  Yihai Cao
Journal:  Nat Rev Clin Oncol       Date:  2010-08-03       Impact factor: 66.675

5.  A Phase II dose titration study of thalidomide for cancer-associated anorexia.

Authors:  Mellar Davis; Wael Lasheen; Declan Walsh; Fade Mahmoud; Leslie Bicanovsky; Ruth Lagman
Journal:  J Pain Symptom Manage       Date:  2011-06-02       Impact factor: 3.612

6.  Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy.

Authors:  Sarah A Reed; Pooja B Sandesara; Sarah M Senf; Andrew R Judge
Journal:  FASEB J       Date:  2011-11-18       Impact factor: 5.191

7.  Endostatin improves cancer-associated systemic syndrome in a lung cancer model.

Authors:  Xia Wang; Rui-Yu Zhan; Yu-Yi Wang; X I Yan; Dan Cao; Yan Li; Yi-Qin Wang; Feng Luo
Journal:  Oncol Lett       Date:  2015-03-17       Impact factor: 2.967

8.  The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer.

Authors:  Ozgur Kemik; Aziz Sumer; Ahu Sarbay Kemik; Ismail Hasirci; Sevim Purisa; Ahmet Cumhur Dulger; Baris Demiriz; Sefa Tuzun
Journal:  World J Surg Oncol       Date:  2010-09-28       Impact factor: 2.754

Review 9.  Cachexia and pancreatic cancer: are there treatment options?

Authors:  Tara C Mueller; Marc A Burmeister; Jeannine Bachmann; Marc E Martignoni
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

10.  Association of interleukin-8 with cachexia from patients with low-third gastric cancer.

Authors:  Bo Song; Dianliang Zhang; Shuchun Wang; Hongmei Zheng; Xinxiang Wang
Journal:  Comp Funct Genomics       Date:  2009-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.